Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

March 23, 2023

Study Completion Date

March 23, 2023

Conditions
Essential Thrombocythemia
Interventions
DRUG

Bomedemstat

Oral administration

Trial Locations (26)

2065

Local Institution, St Leonards

3168

Local Institution, Clayton

5000

Royal Adelaide Hospital, Adelaide

10021

Local Institution, New York

15232

Local Institution, Pittsburgh

27710

Local Institution, Durham

32209

Local Institution, Jacksonville

44195

Cleveland Clinic, Cleveland

45147

Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), Essen

48109

Local Institution, Ann Arbor

50139

CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi, Florence

98109

Local Institution, Seattle

Unknown

Local Institution, Herston

Local Institution, Camperdown

Local Institution, Southport

Local Institution, Jena

Local Institution, Hong Kong

Local Institution, Alessandria

Local Institution, Bologna

Local Institution, Varese

Local Institution, Auckland

Middlemore Hospital, Auckland

Local Institution, Oxford

NW1

Local Institution, London

SE1 9RT

Guys and St Thomas Hospital, London

W12

Local Institution, London

All Listed Sponsors
lead

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

NCT04254978 - Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) | Biotech Hunter | Biotech Hunter